Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Differentiated Thyroid Gland Carcinoma”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Testing effectiveness (Phase 2)UnknownNCT01830504
What this trial is testing

Phase II Pilot Open Label

Who this might be right for
Thyroid Cancers
Hospices Civils de Lyon 47
Large-scale testing (Phase 3)Looking for participantsNCT06475989
What this trial is testing

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Who this might be right for
Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group 264
Testing effectiveness (Phase 2)Study completedNCT02614495
What this trial is testing

Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Hutchison Medipharma Limited 66
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Study completedNCT02702388
What this trial is testing

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Who this might be right for
Thyroid Cancer
Eisai Inc. 241
Not applicableApproved For MarketingNCT03533361
What this trial is testing

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Who this might be right for
Thyroid Cancer
Eisai Inc.
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8
Large-scale testing (Phase 3)Ended earlyNCT03602495
What this trial is testing

Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 204
Not applicableUnknownNCT04858867
What this trial is testing

Reinducing Radioiodine-sensitivity in Radioiodine-refractory DTC Using Lenvatinib (RESET)

Who this might be right for
Differentiated Thyroid Cancer
Leiden University Medical Center 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03914300
What this trial is testing

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland Carcinoma+6 more
National Cancer Institute (NCI) 11
Not applicableUnknownNCT06062563
What this trial is testing

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Who this might be right for
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Study completedNCT02973997
What this trial is testing

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Who this might be right for
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular Carcinoma+23 more
Academic and Community Cancer Research United 57
Large-scale testing (Phase 3)Study completedNCT02966093
What this trial is testing

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Eisai Co., Ltd. 151
Early research (Phase 1)Study completedNCT01413113
What this trial is testing

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Who this might be right for
Recurrent Thyroid CancerStage IVA Follicular Thyroid CancerStage IVA Papillary Thyroid Cancer+4 more
University of Washington 6
Testing effectiveness (Phase 2)UnknownNCT03167385
What this trial is testing

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Who this might be right for
Differentiated Thyroid Carcinoma
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Large-scale testing (Phase 3)UnknownNCT02586337
What this trial is testing

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Who this might be right for
Differentiated Thyroid Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 113
Large-scale testing (Phase 3)Active Not RecruitingNCT03690388
What this trial is testing

Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Who this might be right for
Differentiated Thyroid Cancer
Exelixis 187
Early research (Phase 1)Active Not RecruitingNCT04420754
What this trial is testing

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
AffyImmune Therapeutics, Inc. 70
Early research (Phase 1)Study completedNCT04462471
What this trial is testing

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Who this might be right for
Thyroid CarcinomaThyroid CancerThyroid Cancer, Follicular+3 more
Memorial Sloan Kettering Cancer Center 8
Load More Results